Workin' 9 to 5: From Dolly to Data Centers (e2540)

SHOWNOTESA brisk tour through oil, gas, and U.S. fiscal mechanics, followed by a biotech history chapter and a deep dive on NVIDIA’s sustained dominance. We close with a big healthcare development—“Trump-RX”—and quick hits from Harrow Health’s investor day.[00:00] Intro [00:28] Exhibit C – Oil: $62 is Doing Its Job Hunt frames today’s oil tape: production is rolling off in the U.S., OPEC, and non-OPEC; geopolitical thawing could keep prices soft near term. With Saudi capacity around 12 mb/d and surplus capacity trending toward ~2.5 mb/d by 2026, a “normally supplied” market implies oil trades in the $70s—though swoons into the $50s can happen on the way there.[02:05] Exhibit B – Natural Gas, Power Burn & LNG Gas underperformed, but storage is robust. Power burn was flat ’25 vs ’24 despite “AI, AI” chatter—a surprise tied to coal plant life-extension and a near-term lull in new wind/solar coming online. LNG demand stepped up this year; if power burn resumes climbing, a durable ~$4 gas band becomes more plausible.[03:22] Exhibit A – U.S. Cash Flow & the Shutdown The team walks through the continuing resolution dynamics: House bills vs 60-vote Senate reality, daily vote tactics, and the case for finishing all 12 appropriations. Beyond the political scoreboard, the focus is on process: budgeting via CRs isn’t how the system should work—and markets will parse timing of data releases like jobs.[05:44] Biopharma History (Part 4): From Genzyme to Monoclonals Jason spotlights Genzyme’s rare-disease model (boosted by the Orphan Drug Act), the Human Genome Project’s 13-year blueprint, and the 1996 Dolly milestone foreshadowing cell reprogramming. Genentech’s late-90s antibodies (Rituxan, Herceptin) ushered in targeted oncology—monoclonals remain the highest-grossing class today.[12:09] Next Week: OpenAI—A Controversial History Programming note: the crew will tackle OpenAI’s origin story and flashpoints next week, with Oracle and NVIDIA history episodes likely to follow.[14:19] NVIDIA’s Moat: Cash, CUDA, Cadence (p. 3)Hunt updates the NVIDIA page: zero net debt, >$50B cash, ~$85B run-rate FCF on ~$170B revenue, and modest capex vs hyperscalers. Mike explains why CUDA’s ecosystem and annual product cadence (powered by ~$15B R&D) create a TCO advantage so strong that even “free” AMD GPUs lose in practice; the window for rivals narrows as workloads stay variable.[21:20] Post-Break: ASICs vs. AMD & What’s After LLMs Jason notes the market’s pivot: when buyers do switch from NVIDIA, they’re more often going custom (ASIC/TPU) than to AMD. He adds that frontier researchers expect architectures beyond today’s LLMs to power the next step in reasoning—another reason flexibility favors NVIDIA’s stack for now.[22:43] Healthcare Shake-Up: “Trump-RX” and PBMs A new Medicare direct-to-consumer platform (Pfizer as first partner) could remove PBMs from many transactions, standardize pricing, and simplify Part D decisions. The panel discusses “gross-to-net” dynamics (often ~50% industrywide) and why UnitedHealth’s PBM economics could face pressure; potential annual savings to Medicare could be very large.[27:25] Harrow Health Investor Day: Buying Back Melt Harrow fully acquires the rest of Melt (anesthetic asset) for $8M upfront plus royalties. The team praises the capital allocation arc—spin out in the lean years, re-acquire after Phase 3 success once cash flows stabilize—highlighting optionality beyond ophthalmology (e.g., dentistry).[28:41] Wrap-Up & Next Week Sign-off with a reminder to check the memo. Next episode: OpenAI’s history—then likely Oracle and NVIDIA deep dives.Thanks for listening! If this episode helped clarify markets, share it with a friend and subscribe. Grab the Cash Flow Memo for all exhibits and the ~80-company financials.This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com